Abstract Endometrial atypical hyperplasia (EAH) is a precancerous lesion whose distinction from non-atypical hyperplasia and endometrioid carcinoma carries major therapeutic implications, particularly in young women eligible for fertility-sparing treatment. Because diagnostic reproducibility remains limited, we assessed interobserver concordance for EAH and explored the contribution of PTEN immunohistochemistry, used here as a single, readily available ancillary marker.
